Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation – show that the combined GLP-1 and amylin agonist achieved up ...

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo’s ...

Last year, the Danish company delivered promising early-stage results for amycretin, another GLP-1 option. Amycretin is a dual agonist -- it mimics the action of GLP-1 and another hormone called ...